Search

Displaying results 1591 - 1600 of 9314 in total
  1. Drug

    Insulin aspart

    go.drugbank.com/drugs/DB01306
    ApprovedInvestigational

    to produce or synthesize the insulin needed to manage circulating blood sugar levels. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.

  2. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    It is sold by Pfizer under the name Petinutin.

  3. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation. … [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.

  4. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control … [L47196] Donislecel is particularly beneficial for type 1 diabetic patients with hypoglycemia unawareness, the inability to detect blood glucose dropping and thus unable to prevent further hypoglycemia

  5. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  6. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

  7. Drug

    Warfarin

    go.drugbank.com/drugs/DB00682
    ApprovedInvestigational

    Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.

  8. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency. … Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.

  9. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.

    Products: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 ML
  10. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. … The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).